Hayward, CA - September 16, 2002 - Biolog, Inc. announced
today that it has received another patent on its proprietary miniaturization
technology. This technology is applicable to the company's MicroLog
microbiology identification/characterization (MI) products as well
as the new Phenotype MicroArray(PM) technology. The patent,
number 3,305,322, is granted for testing Biolog's device for liquid
and liquid suspended samples. This brings the number of patents
granted around the PM technology to 18. Biolog's new patent extends
the international scope of protection on this unique technology
which has patents already issued in the last two years in the U.S.
"We believe miniaturization will become more important for
the PM technology as we apply it to applications such as high-throughput
screening of chemical compounds against cells" said Tim Mullane,
President & CEO of Biolog, Inc. "Our miniaturization technology
allows a minimum 10 to 20 fold reduction in sample required for
the company's current assays. It offers the added benefit of single
port inoculation, which reduces the potential for pipetting errors."
The current focus of the company is to extend its current assays
to human cell analysis. Biolog is one of the market leaders in non-clinical
microbiological identification tests and has an active technology-licensing
program for its PM cell assay technology. The company is in discussions
with miniaturization and microfluidics companies about licensing
these patents for applications outside the companies cellular assay
Biolog, a privately held company based in Hayward, CA, is a pioneer
in the development of powerful new cell analysis tools for solving
critical problems in clinical, pharmaceutical, and biotechnology
research and development. The company's Phenotype MicroArray technology
and OmniLog® PM System can be used in the discovery and development
of new drugs as well as bioactive agents for animal and plant applications.
Further information can be obtained at the company's website, www.biolog.com.